

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**弘達金融控股有限公司**

**HongDa Financial Holding Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1822)**

**VOLUNTARY ANNOUNCEMENT**  
**ACQUISITION OF 30% EQUITY INTEREST IN CHONGYANG HEALTH**  
**DATA TECHNOLOGY (SHENZHEN) COMPANY LIMITED\***

This announcement is made by HongDa Financial Holding Limited (the “**Company**”, together with its subsidiaries, collectively referred to as the “**Group**”) on a voluntary basis.

**EQUITY TRANSFER AGREEMENT**

The board (the “**Board**”) of directors of the Company is pleased to announce that on 7 June 2018 (after trading hours), Hongshen Information Consulting (Zhuhai) Company Limited\* (弘深信息諮詢(珠海)有限公司), a wholly-owned subsidiary of the Company, entered into an equity transfer agreement with a third party (the “**Transferor**”) independent of the Company and its connected persons (as defined under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)), pursuant to which Hongshen Information Consulting (Zhuhai) Company Limited\* has conditionally agreed, through itself or its directly wholly owned subsidiary (the “**Subsidiary**”), to acquire 30% equity interest in the registered capital of Chongyang Health Data Technology (Shenzhen) Company Limited\* (重陽健康數據技術(深圳)有限責任公司) (“**Target Company**”) owned by the Transferor (the “**Acquisition**”). Upon completion of the Acquisition, the Subsidiary will contribute RMB30,000,000 (equivalent to approximately HK\$36,750,000) to the registered capital of the Target Company pursuant to the terms of the articles of association of the Target Company. The Subsidiary will own 30% equity interest in the Target Company and the remaining 70% equity interest will be held by two existing shareholders of the Target Company (other than the Transferor) who are third parties independent of the Company and its connected persons (as defined under the Listing Rules).

\* The English translation of the Chinese names in this announcement where indicated is included for information only.

## **INFORMATION ON THE TARGET COMPANY**

The Target Company is a sino-foreign equity joint venture company established under the laws of the People's Republic of China and is primarily engaged in the development of intelligent communication devices and healthcare data software, and the provision of health and wellness management consulting services.

To the best of the knowledge, information and belief of the directors of the Company having made all reasonable enquiries, each of the Transferor and its ultimate beneficial owner(s) is a third party independent of the Company and its connected persons (as defined under the Listing Rules.)

## **INFORMATION OF THE COMPANY AND THE GROUP**

The Company is an exempted company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange. The Group is principally engaged in the business of car rental businesses, material trading businesses and providing financing services. The Group will continue to complete its business transformation and implement a diversified development strategy while vigorously expanding its financial and asset management businesses.

## **REASONS FOR AND BENEFIT OF THE ACQUISITION**

With its diversified development strategy, the Group has been actively seeking new business opportunities in order to expand its business portfolio. The Group is proactively exploring high-quality innovative technology projects, aiming to solidify the foundation of its business and seeking opportunities in medical and healthcare sectors.

Under the profound reforms in national healthcare system, increasing health awareness and high demand for healthcare service in China, medical and healthcare sectors have seen steady and continual growth, with enormous development potential. Investing in the Target Company enables the Group to tap into the emerging technology industry with promising prospect, which is in line with the Company's strategy to invest in high-quality projects in innovative technology, and to develop and explore medical and healthcare business, as well as to further expand its operation scale in China's medical market. Looking forward, technological healthcare products will be the key focus of the medical industry development, and its product will be closely related and complementary to the medical industry. Accordingly, with a view to enhance the Group's long-term development potentials, this Acquisition will foster the Group's development in China's medical industry and is in the interests of the shareholders as a whole.

## LISTING RULES IMPLICATIONS

Since all applicable percentage ratios in respect of the Acquisition under the Listing Rules are lower than 5%, the Acquisition does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules. This announcement is made voluntarily by the Company.

**As the Acquisition is subject to fulfilment and/or waiver, if applicable, of various conditions precedent which may or may not be fulfilled, there is no assurance that the Acquisition will be completed. Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**HongDa Financial Holding Limited**  
**Chen Xiaohang**  
*Executive Director & CEO*

Hong Kong, 7 June 2018

*As at the date of this announcement, the Board comprises Ms. Tung Shun (Chairman) and Ms. Chen Xiaohang (CEO) as executive directors; Mr. Li Xiaolu (Vice-Chairman) and Ms. Wang Li as non-executive directors; and Mr. Wong Yiu Kit, Ernest and Mr. Zhao Xianming as independent non-executive directors.*

*For illustration purpose only and unless otherwise stated, conversion of RMB into HK\$ in this announcement is based on the exchange rate of RMB1=HK\$1.225 and rounded to thousand. Such conversion should not be construed as a representation that any amount have been, could have been, or maybe, exchanged at this or any other rate.*